- Becton Dickinson’s CFO is set to depart, and the company is searching for a permanent replacement.
- Vitor Roque has been appointed as the interim CFO. He previously served as the senior vice president of finance, business units, and corporate financial planning and analysis.
- The preliminary revenue for the fourth quarter is approximately $5.9 billion, close to the estimate of $5.91 billion.
- The company’s fiscal 2025 revenue guidance is around $21.8 billion, down from earlier estimates of $21.8 billion to $21.9 billion and compared to a market estimate of $22.8 billion.
- Becton Dickinson expects adjusted EPS to be at or above the midpoint of its prior guidance range of $14.30 to $14.45.
- As of August 7, Becton Dickinson experienced a positive market response after increasing its full-year adjusted EPS forecast.
- Investment consensus on Becton Dickinson includes 5 buy ratings, 9 holds, and 0 sells.
Becton Dickinson and Co on Smartkarma
Analysts on Smartkarma are closely covering Becton Dickinson and Co, with Baptista Research recently publishing an insightful report titled “Becton Dickinson Fuels Biologics Boom With 70+ GLP-1 Agreements; What Lies Ahead?“. The report delves into BD’s third fiscal quarter results for 2025, outlining key positive developments and challenges faced by the company. BD’s revenue showed strong growth, increasing by 8.5% to $5.5 billion, with organic growth at 3%. Additionally, the company saw improvements in its adjusted gross margin and adjusted operating margin, a positive sign for investors.
A look at Becton Dickinson and Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Becton Dickinson and Co, a global medical technology company, has a solid long-term outlook. With balanced scores across Value, Dividend, Growth, Resilience, and strong Momentum, the company seems well-positioned in the market. Their Value, Dividend, Growth, and Resilience all received a score of 3, indicating stability and potential for growth. Additionally, their Momentum scored 4, suggesting a strong positive trend in the company’s performance.
Becton, Dickinson and Company, known for its development, manufacturing, and sale of medical devices, instrument systems, and reagents, serves various sectors including healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. With consistent scores across important factors, the company’s overall outlook appears promising for investors seeking a reliable and potentially growing investment option in the medical technology sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
